What Alkermes (ALKS) Said on Its Q3 Earnings Call
Alkermes (ALKS) expects Q4 proprietary product net sales of $400M-$420M and $1.6B for full-year 2026. Q3 GAAP net income was $16.3M, EBITDA $63M, and cash $787.6M. The company is advancing its orexin pipeline, with Phase III trials for alixorexton in narcolepsy and IH, and Phase II trials for ALKS 7290 in ADHD and depression.
How this was made

The 30-second read
Why it matters
The most tradable elements are the explicit Q4 proprietary product net sales range, full-year 2026 net sales expectations for the proprietary portfolio, and the planned regulatory and clinical milestones that shape probability-weighted value for LUMRYZ and alixorexton. Cost structure commentary (COGS step-up and R&D ramp) provides a counterweight for margin expectations.
Market read
Provides forward-looking sales guidance and a structured timeline of clinical readouts and potential IH launch timing, which can drive biotech valuation and positioning.
What to watch
The article notes “somewhat marginal” initial impact from Takeda’s anticipated orexin launch, but does not quantify competitive pricing or uptake risk; investors may discount the assumption until real-world market share data emerges.
Background
This is a summary of Alkermes’ Q3 earnings call commentary, covering 2026 sales expectations, 2027 cost outlook, and clinical progress across LUMRYZ (IH/narcolepsy) and orexin/ADHD programs.
Ticker impact
Alkermes guided proprietary product net sales for Q4 ($400M-$420M) and reiterated 2026 expectations, while detailing LUMRYZ and orexin pipeline timelines.
Likely upward bias as investors price in LUMRYZ sales trajectory and upcoming Phase III milestones, partially offset by higher COGS and R&D spend.
The article provides concrete forward-looking sales expectations and multiple pipeline readout dates (mid-2027, year-end/early 2027, March 2028 potential launch), which typically drive biotech risk/reward repricing. It also flags higher COGS tied to LUMRYZ inventory accounting and rising R&D, which can temper the reaction.
Market effects
Reinforces investor focus on CNS/central nervous system drug pipelines and orexin-therapy competitive dynamics, including read-through from Takeda’s anticipated orexin launch.
Limited direct regional impact; primarily US-listed biotech sentiment.
Moderate, as orexin therapy competition and Phase III timelines can influence global CNS biotech risk appetite.
Counterpoint
The call emphasizes higher near-term costs (COGS and R&D) and relies on future regulatory interactions, so the near-term earnings power may not improve as quickly as the sales guidance implies.
Key entities
- companyAlkermes plc
NASDAQ-listed biopharmaceutical company focused on CNS therapies; subject of the earnings-call summary.
- productLUMRYZ
Alkermes’ oxybate therapy referenced for IH and narcolepsy development and supplemental NDA plans.
- drug_candidatealixorexton
Orexin 2 receptor agonist in Phase III for narcolepsy and IH, with Vibrance-3 Phase II enrollment completed.
- drug_candidateALKS 7290
Orexin-related candidate in Phase Ib/Phase II studies for ADHD and adjunctive MDD.
- drug_candidateALKS 4510
Planned Phase II study for fatigue associated with multiple sclerosis or Parkinson’s disease.


